# NCT03331198 (NCT03331198)

> Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03331198
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Juno Therapeutics, a Subsidiary of Celgene
- Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
- Interventions: JCAR017 (lisocabtagene maraleucel); JCAR017 (lisocabtagene maraleucel) + ibrutinib; JCAR017 (lisocabtagene maraleucel) + venetoclax
- Enrollment: 320
- Primary outcome: Phase 1 JCAR017 monotherapy arm: adverse events
- Primary outcome: Phase 1 JCAR017 monotherapy arm: laboratory abnormalities
- Primary outcome: Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events
- Primary outcome: Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities
- Primary outcome: Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm
- Primary outcome: Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events
- Primary outcome: Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities
- Primary outcome: Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm
- Primary outcome: Phase 2 JCAR017 monotherapy expansion arm
- Primary outcome: Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)

## Commentary we found

- YouTube: 37
- X threads: 19
- Podcasts: 17

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03331198

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03331198", "email": "<work email>"}; the inbox owner confirms by the emailed link.